Clinical Trial Update: Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure [Phase 2]

View source ↗

Summary

Phase 2 study assessing the immunogenicity of the rVSV-ZEBOV-GP Ebola vaccine for pre-exposure prophylaxis in individuals at potential occupational risk; the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Ervebo (rVSV-ZEBOV-GP) vaccine (recombinant vesicular stomatitis virus vaccine expressing Zaire ebolavirus glycoprotein (rVSV-ZEBOV-GP))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Healthy Volunteers | Phase 2 | Status: COMPLETED